You’ve probably heard the stories by now. Someone starts taking Ozempic or Wegovy to drop a few pounds, and suddenly they stop biting their nails. Or they lose their taste for wine. Or they effortlessly quit a 20-year smoking habit.
For a while, this was just cocktail party chatter. But now, the data is catching up to the anecdotes.
A new study involving more than 600,000 people suggests that GLP-1 weight-loss and diabetes drugs might do a lot more than shrink your waistline. They appear to short-circuit addiction across the board, from alcohol and nicotine to opioids and cocaine.
If you’re skeptical of miracle drugs, I don’t blame you. I am too. But the numbers coming out of this research are hard to ignore, and they could seriously shift how we treat substance abuse.
What the numbers actually say
Researchers at the VA St. Louis Health Care System and Washington University School of Medicine recently dug into the medical records of more than 600,000 veterans with diabetes. They compared patients taking GLP-1 medications with those taking older diabetes drugs.
According to the findings published by Washington University School of Medicine, the results were staggering. Here’s what they found:
- Reduced risk of new addictions: For people who didn’t already have a substance abuse problem, the risk of developing one dropped by 18% for alcohol, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids.
- Dramatically lower mortality: The most profound impact was seen in people already struggling with severe addiction. GLP-1 users experienced 50% fewer substance-related deaths.
- Fewer medical emergencies: The data also showed 39% fewer overdoses and 26% fewer drug-related hospitalizations.
Turning off the noise
So, how does a diabetes shot stop you from craving a cigarette?
It comes down to how these drugs rewire your brain’s reward system. GLP-1 medications mimic a hormone that makes you feel full. But that hormone doesn’t just act on your stomach; it also crosses into the brain’s reward center.
Normally, addictive substances trigger a flood of dopamine, creating a powerful loop of craving and reward. GLP-1 drugs seem to dampen that dopamine signaling. They turn down the volume on what doctors call drug noise or food noise.
The substance stops being rewarding, so the craving fades away.
What this means for your wallet
Let’s talk about the practical side. Addiction isn’t just a health crisis; it’s a financial catastrophe. The cost of rehab, lost wages, legal trouble, and medical emergencies can wipe out a family’s life savings faster than almost anything else. Even the daily cost of the habit itself adds up fast.
Currently, these drugs are expensive. GLP-1 prescriptions can easily cost over $1,000 a month out of pocket if your insurance doesn’t cover them. And insurance companies are notoriously stingy about approving them for anything other than specific, FDA-approved conditions like diabetes or severe obesity.
(Related: See “Health Care Costs Are Set to Skyrocket: 7 Trends You Should Know About.”)
But if the FDA eventually approves these medications for treating addiction, insurance coverage will likely follow. That could make them accessible to millions of people who desperately need an effective intervention.
As the Associated Press notes, we’re not quite at the point where doctors are prescribing Ozempic solely to get you to stop smoking. We need more clinical trials to understand the long-term effects and figure out exactly who benefits most.
But if you’re already taking a GLP-1 for diabetes or weight loss, don’t be surprised if your worst habits suddenly start to disappear. It’s not a coincidence. It’s just science doing its job.
